Enfortumab vedotin + pembrolizumab
Checked 2026-09-09
Locally advanced or metastatic urothelial cancer, first line, regardless of cisplatin eligibility
One cycle
every 21 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
| 1.25 mg/kg (maximum 125 mg) | IV | D1, 8 | ||
Pembrolizumab Monoclonal antibody (anti-PD-1) | 200 mg | IV | D1 | or 400 mg every 6 weeks |
Cycles
until progression; pembrolizumab up to 35 cycles
21-day cycle
Emetogenicity
Low (10-30%)
G-CSF
Not routine
Notes
- Skin reactions (including SJS/TEN), peripheral neuropathy and hyperglycaemia are enfortumab's signals; hold for glucose above 13.9 mmol/L (250 mg/dL).
Used in
Trials
Products
Source
EV-302 / KEYNOTE-A39, NEJM 2024
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Gemcitabine + cisplatin
Advanced biliary tract cancer first line (with durvalumab or pembrolizumab); cisplatin-eligible urothelial cancer
every 21 days × 8
Sacituzumab govitecan
Metastatic TNBC after two lines (one for metastatic disease); HR-positive after endocrine therapy and two chemotherapies
every 21 days
Dose-dense MVAC
Muscle-invasive bladder cancer, cisplatin-eligible, before cystectomy
every 14 days × 3-4
Intravesical BCG, induction and maintenance
High-risk non-muscle-invasive bladder cancer after complete TURBT
weekly × 6